Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,174 across all filing types
Latest filing 2024-05-21 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Intimation regarding allotment of 122374 shares under ESOP.
Regulatory Filings Classification · 100% confidence The document text is extremely short (516 characters) and contains only a digital signature block with no substantive content related to financial reports, announcements, or filings. There is no mention of any report type, regulatory body, fiscal period, or corporate event. Given the lack of content and the nature of the text, it does not fit any specific filing category and should be classified as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings.
2024-05-21 English
U.S. FDA Inspection of the Company''s Somerset manufacturing facility.
Regulatory Filings Classification · 95% confidence The document is a disclosure letter addressed to stock exchanges regarding a U.S. FDA inspection at the company's manufacturing facility. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The document is short (1912 characters) and serves as an announcement of an event (FDA inspection and Form-483 issuance) rather than a detailed report or financial statement. It does not contain financial data, management discussion, or audit information. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and disclosures that do not fit other specific categories.
2024-05-19 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges regarding a U.S. FDA inspection at the company's manufacturing facility. It references regulatory compliance under SEBI Listing Obligations but does not contain any financial data, audit results, or detailed report content. The document is only informing about an event (FDA inspection and Form-483 issuance) and the company's response plan. It is not an annual report, audit report, earnings release, or any detailed financial or management report. The length is short (1909 characters), and it serves as a regulatory disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-05-19 English
Loss of Share Certificates
Regulatory Filings Classification · 100% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. It details the loss of share certificates and the request for stop transfer. It is addressed to stock exchanges and signed by the company secretary. The document is short (2800 characters) and is a regulatory compliance communication rather than a financial report or announcement of financial results. It does not contain financial data, management discussion, or shareholder voting results. It is not an announcement of a report but a regulatory filing related to share certificate handling. Therefore, it fits best under Regulatory Filings (RNS).
2024-05-17 English
Intimation regarding loss of share certificate by the share holder.
Regulatory Filings Classification · 95% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. It details the loss of share certificates and the request for stop transfer. It is addressed to stock exchanges and signed by the company secretary. The document is short (2810 characters) and is a regulatory compliance communication rather than a financial report or announcement of voting results, management changes, or capital changes. It does not contain financial data or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-05-17 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2024-05-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.